In CMS4, patients with KRAS wild-type tumours responded better to cetuximab compared to patients treated with bevacizumab (Fig. 5b, d; KRAS wild types: p = 0.02, HR = 0.57 [0.35–0.93]; pint = 0.02, FDRint < 0.2), for which the resampling-based adjusted treatment effect yielded HR = 0.70 [0.25–2.35] with padj = 0.14 (Fig. 5b, d). The gene discussed is KRAS; the disease is neoplasm.